IL34 and cervical cancer: In keeping with this, we found that cervical cancer patients expressing low levels of IL34 have a significantly worse survival outcomes than those expressing high levels of IL34 (Figure 6C), suggesting that disruption of IL34-mediated KC-LC interactions potentially delays LCs development (Figure 4G) and has a deleterious effect on anti-tumor immunity.